🌸 Bioidentical Hormone Compounding Safety Simulator

Compounded vs FDA-Approved Bioidentical Hormones

Placeholder lead: compounded products skip standard FDA approval review.

• None: FDA review (Placeholder: compounded skip review)
• Many: Approved options (Placeholder: FDA-approved alternatives exist)
• Rare: Batch testing (Placeholder: compounding pharmacies vary)
• Common: Prescriber use (Placeholder: widely prescribed off-label)

Regulatory pathway differences

Placeholder: compounded products are pharmacy-made, not FDA-batch-approved.

Lack of Standardized Quality Testing

Placeholder lead: many compounding pharmacies lack routine potency testing.

• Up to 25%: Potency variance (Placeholder: found in some studies)
• Inconsistent: Sterility testing (Placeholder: not always required)
• Optional: Third-party audits (Placeholder: voluntary accreditation)
• Nonzero: Contamination risk (Placeholder: past outbreak examples)

Testing gaps across pharmacies

Placeholder: testing rigor differs widely between compounding facilities.

Dose Consistency Variability Concerns

Placeholder lead: compounded batches can differ from labeled dose.

• Variable: Batch-to-batch (Placeholder: dosing can drift)
• ±10–30%: Assay deviation (Placeholder: reported ranges)
• ±5%: Approved variance (Placeholder: FDA manufacturing limit)
• Under/over dose: Patient impact (Placeholder: possible outcomes)

Why consistency matters

Placeholder: hormone therapy requires precise, reproducible dosing.

Marketing Claims vs Evidence Gap

Placeholder lead: bioidentical marketing often outpaces clinical trial data.

• Limited: RCT support (Placeholder: few large trials)
• Unregulated: "Natural" claims (Placeholder: marketing term, not clinical)
• Incomplete: Safety data (Placeholder: long-term data sparse)
• Cautionary: Society guidance (Placeholder: major bodies urge caution)

Claims vs clinical trials

Placeholder: many benefit claims lack robust trial support.

When Compounding May Be Appropriate

Placeholder lead: compounding can help with allergies or unavailable dose forms.

• Valid use: Allergy cases (Placeholder: excipient allergy example)
• Valid use: Unavailable strength (Placeholder: dose not commercially made)
• Not advised: Routine substitute (Placeholder: avoid as default choice)
• Required: Physician oversight (Placeholder: monitored prescribing needed)

Narrow appropriate scenarios

Placeholder: compounding fits niche cases, not routine therapy.

Placeholder highlight: always discuss compounding risks with a prescriber.